Powered By
Below is a listing of treatments and therapies for IgA Nephropathy. Click on one to read more information or connect with others currently using it.
Overview
Fabhalta is approved by the U.S. Food and Drug Administration (FDA) to reduce proteinuria (excess protein in urine) in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of rapid disease…
Overview
Filspari is approved by the U.S. Food and Drug Administration (FDA) to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression. The drug is…
Overview
Tarpeyo is approved by the U.S. Food and Drug Administration (FDA) to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression. Tarpeyo…
Overview
Vanrafia is approved by the U.S. Food and Drug Administration (FDA) under accelerated approval to reduce proteinuria (excess protein in the urine) in adults with primary immunoglobulin A nephropathy (IgAN) who…
Overview
Voyxact is approved by the U.S. Food and Drug Administration (FDA) to reduce proteinuria (excess protein in the urine) in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease…
Become a member to get even more
Join
